Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Apr 30, 2022 3:21pm
211 Views
Post# 34645088

RE:Im curious for year end financials

RE:Im curious for year end financials
Stutters wrote:
2021 financials had ate ear marked at 72 million in cash. 2022 should be around 36-38 mill or half the cash. Its been 1 heck of a year folks.


Seriously - get over it !
They didn't pick up the cash so they could nurse it in the bank.

-------------------

Let's assume $55M in cash right now.
By September I predicted there's a good chance we get about $7.5M - let's go with $8M now.
So at $2.5M in avg monthly spend ... by year's end ... we'll drop $20M.

In the bank on Jan 1 2023 - could be as high as $43M and as low as $35M (my guess).

As you know ... this is drug development and they picked up the cash for a really good reason.
And the spend is going to grow - there is no doubt. 

To cry about cash spend is like saying you have no idea what the goal is here.

Let me help ... expensive drug development.

That's the way it's supposted to be!  Get over it !


: )
<< Previous
Bullboard Posts
Next >>